{Reference Type}: Journal Article
{Title}: Multidisciplinary systemic and local therapies for metastatic renal cell carcinoma: a narrative review.
{Author}: Zarba M;Fujiwara R;Yuasa T;Koga F;Heng DYC;Takemura K;
{Journal}: Expert Rev Anticancer Ther
{Volume}: 0
{Issue}: 0
{Year}: 2024 Jun 3
{Factor}: 3.627
{DOI}: 10.1080/14737140.2024.2362192
{Abstract}: <B>UNASSIGNED: </B>Systemic and local therapies for patients with metastatic renal cell carcinoma (mRCC) are often challenging despite the evolution of multimodal cancer therapies in the last decade. In this review, we will focus on recent multidisciplinary approaches for patients with mRCC.<BR><B>UNASSIGNED: </B>Systemic therapies for patients with mRCC have been garnering attention particularly after the approval of immuno-oncology (IO) agents, including anti-programmed death 1/programmed death-ligand 1. IO combinations have significantly prolonged overall survival in patients with mRCC in the first-line setting. Regarding local therapies, cytoreductive nephrectomy (CN) has become less common in the post-Cancer du Rein Metastatique Nephrectomie et Antiangiogéniques (CARMENA) trial era, even though CN may still benefit selected patients with mRCC. In addition, metastasis-directed local therapies, namely metastasectomy or stereotactic radiotherapy, particularly for oligo-metastatic lesions or brain metastases, may have a prognostic impact. Several ablative techniques are also evolving while maintaining high local control rates with acceptable safety.<BR><B>UNASSIGNED: </B>Multimodal cancer therapies are essential for conquering complex cases of mRCC. Modern systemic therapies including IO-based combination therapy as well as local therapies including CN, metastasectomy, stereotactic radiotherapy, and ablative techniques appear to improve oncologic outcomes of patients with mRCC, although appropriate patient selection is indispensable.